Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Wisconsin

CNS medication trials in Wisconsin

23 CNS medication studies are recruiting participants at sites in 6 cities across Wisconsin as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Wisconsin city with a recruiting study

By research area: Migraine (8), Multiple Sclerosis (7), Parkinson's Disease (6), Depression (2).

Milwaukee (13), Madison (7), Kenosha (3), Greenfield (1), Marshfield (1), Mequon (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Depression: recently updated in Wisconsin

Basic details from each study's public record (the 12 most recently updated of 23). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Recruiting in
    Madison
    Registry record
    NCT07002034 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Wisconsin on ClinicalTrials.gov.

Parkinson's disease: recently updated in Wisconsin

  1. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Madison
    Registry record
    NCT06966700 · updated
  2. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Recruiting in
    Madison
    Registry record
    NCT06989112 · updated
  3. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Madison
    Registry record
    NCT06345729 · updated
  4. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Recruiting in
    Milwaukee
    Registry record
    NCT06680830 · updated
  5. A Study of Buntanetap in Participants With PD

    • Phase 2/3
    • Ages 40 to 85
    • All sexes
    Sponsor
    Annovis Bio Inc.
    Recruiting in
    Milwaukee
    Registry record
    NCT07284784 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Wisconsin on ClinicalTrials.gov.

Multiple sclerosis (MS): recently updated in Wisconsin

  1. A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Recruiting in
    Milwaukee
    Registry record
    NCT07067463 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Wisconsin on ClinicalTrials.gov.

Migraine: recently updated in Wisconsin

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Recruiting in
    Marshfield · Milwaukee
    Registry record
    NCT06972056 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Recruiting in
    Kenosha
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Recruiting in
    Kenosha
    Registry record
    NCT07674654 · updated
  4. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Recruiting in
    Kenosha · Madison
    Registry record
    NCT04649242 · updated
  5. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Recruiting in
    Madison
    Registry record
    NCT04743141 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Wisconsin on ClinicalTrials.gov.

Ask about studies in Wisconsin

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call